Work for Mirum Pharmaceuticals, Inc.?

Claim Your Profile

Mirum Pharmaceuticals, Inc. Logo Image

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. has reached its limit for free report views.

About Mirum Pharmaceuticals, Inc.

51-200 Employees
Based in Foster City, California

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. The company has initiated a rolling NDA submission for maralixibat in the treatment of patients with cholestatic pruritus associated with ALGS and expects to complete the submission in the first quarter of 2021. Additionally, the company plans to submit a marketing authorization application to the European Medicines Agency for maralixibat in the treatment of patients with PFIC2 in the fourth quarter 2020.

Ticker:
MIRM
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol